Latest news with #DERM
Yahoo
15-05-2025
- Business
- Yahoo
Journey Medical Corp (DERM) Q1 2025 Earnings Call Highlights: Amrosi Launch Boosts Margins ...
Net Revenue: $13.1 million for Q1 2025, compared to $13 million for Q1 2024. Amrosi Revenue: $2 million from the initial launch included in Q1 2025 net product sales. Gross Margin: Increased to 64% in Q1 2025 from 54% in Q1 2024. R&D Costs: Nil in Q1 2025, compared to $7.9 million in Q1 2024. SG&A Expenses: Increased to $10.6 million in Q1 2025 from $8.4 million in Q1 2024. Net Loss: $4.1 million or $0.18 per share for Q1 2025, compared to $10.4 million or $0.53 per share for Q1 2024. Cash Position: $21.1 million at the end of Q1 2025, compared to $20.3 million at December 31, 2024. Commercial Payer Access: Approximately 30% of covered commercial insured lives now have access to Amrosi. Warning! GuruFocus has detected 8 Warning Signs with DERM. Release Date: May 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Journey Medical Corp (NASDAQ:DERM) successfully launched Amrosi, a new oral rosacea treatment, contributing $2 million to the first quarter 2025 net product sales. The company reported a gross margin increase to 64% in Q1 2025, up from 54% in the prior year, due to a favorable product sales mix and reduced product costs. Amrosi's market introduction has been well-received, with positive feedback from healthcare providers and strong initial prescription volumes. Approximately 30% of commercially insured lives now have access to Amrosi, up from 20% in the previous quarter, indicating progress in payer coverage. The inclusion of Amrosi in the National Rosacea Society's treatment algorithms and its publication in JAMA Dermatology are expected to drive further clinical adoption and market uptake. Net revenue for Q1 2025 was only slightly higher at $13.1 million compared to $13 million in Q1 2024, indicating limited overall revenue growth. Legacy products experienced a decline, with a noted decrease in prescriptions for Accutane due to increased competition and aggressive pricing by new market entrants. SG&A expenses increased by $2.1 million to $10.6 million in Q1 2025, reflecting higher investments in commercial infrastructure for the Amrosi launch. The company reported a net loss to common shareholders of $4.1 million for Q1 2025, although this was an improvement from the $10.4 million loss in Q1 2024. There is uncertainty regarding the sustainability of initial Amrosi sales, as the Q1 revenue included significant stocking, and future revenues will need to reflect actual demand. Q: Can you provide insights on the Q1 revenues for Amrosi and expectations for future quarters? A: Claude Maraoui, President and CEO, explained that the $2 million in Q1 revenues was largely due to stocking the distribution channel. The salesforce began actively promoting Amrosi in April, and while no specific revenue expectations for Q2 were provided, the company is optimistic about continued growth and will share updates at the end of Q2. Q: How is the legacy business performing, particularly with products like Cubrexa and Accutane? A: Claude Maraoui noted a decline in legacy brands due to generic competition. However, Cubrexa is performing well, with a 15% increase in prescriptions year-over-year, despite new competition. Accutane faced challenges from new competitors but showed a 10% growth from Q4 2024 to Q1 2025, indicating stabilization. Q: What is the current inventory level in the distribution channel, and how do you anticipate it changing? A: Claude Maraoui stated that the inventory level is typically between 2 to 4 weeks, depending on the ramp-up. The company is focusing on specialty pharmacies that dermatologists frequently use, and the inventory level will adjust as demand grows. Q: What feedback have you received from prescribers about Amrosi, and who are the primary prescribers? A: Claude Maraoui shared that feedback has been positive, with prescribers impressed by Amrosi's efficacy and tolerability. The initial focus is on new patients, with expectations that prescribers will switch existing patients to Amrosi as they gain confidence in the product. Q: Is there any feedback from doctors regarding Amrosi's impact on erythema, even though it's not in the label? A: Claude Maraoui mentioned anecdotal feedback from doctors noting significant erythema reduction, which is supported by data published in JAMA Dermatology. The company plans to build on this data to inform providers about Amrosi's impact on erythema. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
01-05-2025
- Health
- Yahoo
New AI tool to spot skin cancer to be used in NHS
Adults with suspected skin cancer may be initially assessed with a new AI tool after it was approved for NHS use. The National Institute for Health and Care Excellence (Nice) said that the technology, which has been conditionally approved for the next three years, has the potential to reduce waiting times. It comes as health experts issued a warning over sun cream ahead of the Bank Holiday weekend. Melanoma Focus said a large proportion of Britons are frequently letting themselves burn, putting themselves at a higher risk of deadly skin cancer. The new artificial intelligence (AI) tool, DERM (Deep Ensemble for Recognition of Malignancy), works by analysing images of moles or skin lesions to see whether they are potentially cancerous. The tool, developed by Skin Analytics, can be used by healthcare workers who use a smartphone with a high quality magnifying lens attached, also known as a dermoscopic lens, to take images of suspicious moles, or skin lesions. The images are then uploaded on to DERM's online platform, which uses AI to analyse the images. For patients whose moles or lesions are identified as potentially cancerous, a specialist skin doctor, known as dermatologist, will review the case and come up with a plan for the patient. People whose moles or lesions are not suspicious are either offered reassurance and advice or can be put on a 'non-urgent pathway'. Nice said that early evidence suggests the automated use of the tool could 'approximately halve the number of referrals to dermatologists within the urgent skin cancer pathway'. It has been 'conditionally approved' for the next three years, while further evidence is collected, Nice said. 'DERM has shown promising results in its ability to accurately distinguish between cancerous and non-cancerous skin lesions, with evidence suggesting it could halve the number of referrals to dermatologists within the urgent skin cancer pathway while maintaining patient safety,' said Dr Anastasia Chalkidou, healthtech programme director at Nice. 'Our evaluation shows this technology maintains diagnostic accuracy while reducing the burden on specialist dermatology services. By implementing this system within existing pathways, we can ensure patients get the right care more quickly.' Ashley Dalton, minister for public health and prevention, said: 'By embracing the power of AI, this exciting technology could help us slash waiting times — meaning that people with suspected skin cancer get the help they need, or peace of mind, faster.' Neil Daly, chief executive of Skin Analytics said: ''We're incredibly proud of the work we've been doing with the NHS over the last five years to achieve this recommendation from Nice. Having seen more than 165,000 patients and found more than more than 15,500 cancers since launching, we are ready to make our Class III autonomous skin cancer AI available to more UK patients.' The British Association of Dermatologists said in a statement: 'Until further evidence is generated, the British Association of Dermatologists recommends that all patients should have some input from a dermatologist. 'Implementation of AI must be underpinned by patient safety, with a clear understanding of the benefits and limitations.' The Association said that AI has 'the potential to transform dermatology services' but said that more real-world evidence is needed. It comes as Melanoma Focus warned about the dangers of sunburn among Britons. 'It is essential that everyone understands the risks associated with sunburn and prioritises sun protection by using factor 30+ sunscreen, wearing a hat, seeking shade and covering up in the heat of the day,' said Susanna Daniels, chief executive of Melanoma Focus. A poll by Melanoma Focus of 2,000 people aged 16 and over in the UK that almost half (49%) said they are sunburned at least once a year, with higher numbers reported in younger age groups. Ms Daniels added: 'This data is extremely concerning as we know that more than five sunburns in your lifetime doubles your risk of melanoma, so burning every year has potentially long-term dangerous consequences. 'Nearly nine in 10 melanomas are preventable, yet the UK has more deaths from melanoma per year than Australia.' The poll also found that 19% said they 'rarely' wear sun cream in the UK between May and September, 8% said they 'never' use sun cream in the UK during this period. Almost one in 10 (9%) said they never wear sun cream at all. Reasons for avoiding sun cream in the UK included people not expecting to burn; forgetting to apply sun cream and 8% said sun cream is 'too expensive'. Sign in to access your portfolio
The Herald Scotland
30-04-2025
- Health
- The Herald Scotland
New AI tool to spot skin cancer to be used in NHS
It comes as health experts issued a warning over sun cream ahead of the Bank Holiday weekend. Melanoma Focus said a large proportion of Britons are frequently letting themselves burn, putting themselves at a higher risk of deadly skin cancer. AI is being deployed to speed up the diagnosis of skin cancer and free up capacity within dermatology. DERM assesses and classifies scans of moles or skin lesions that have been taken by a healthcare professional, after patient is referred by a GP for suspected skin cancer. — Bolton NHS Foundation Trust (@boltonnhsft) April 2, 2025 The new artificial intelligence (AI) tool, DERM (Deep Ensemble for Recognition of Malignancy), works by analysing images of moles or skin lesions to see whether they are potentially cancerous. The tool, developed by Skin Analytics, can be used by healthcare workers who use a smartphone with a high quality magnifying lens attached, also known as a dermoscopic lens, to take images of suspicious moles, or skin lesions. The images are then uploaded on to DERM's online platform, which uses AI to analyse the images. For patients whose moles or lesions are identified as potentially cancerous, a specialist skin doctor, known as dermatologist, will review the case and come up with a plan for the patient. People whose moles or lesions are not suspicious are either offered reassurance and advice or can be put on a 'non-urgent pathway'. Nice said that early evidence suggests the automated use of the tool could 'approximately halve the number of referrals to dermatologists within the urgent skin cancer pathway'. It has been 'conditionally approved' for the next three years, while further evidence is collected, Nice said. 'DERM has shown promising results in its ability to accurately distinguish between cancerous and non-cancerous skin lesions, with evidence suggesting it could halve the number of referrals to dermatologists within the urgent skin cancer pathway while maintaining patient safety,' said Dr Anastasia Chalkidou, healthtech programme director at Nice. 'Our evaluation shows this technology maintains diagnostic accuracy while reducing the burden on specialist dermatology services. By implementing this system within existing pathways, we can ensure patients get the right care more quickly.' Ashley Dalton, minister for public health and prevention, said: 'By embracing the power of AI, this exciting technology could help us slash waiting times — meaning that people with suspected skin cancer get the help they need, or peace of mind, faster.' Neil Daly, chief executive of Skin Analytics said: ''We're incredibly proud of the work we've been doing with the NHS over the last five years to achieve this recommendation from Nice. Having seen more than 165,000 patients and found more than more than 15,500 cancers since launching, we are ready to make our Class III autonomous skin cancer AI available to more UK patients.' The British Association of Dermatologists said in a statement: 'Until further evidence is generated, the British Association of Dermatologists recommends that all patients should have some input from a dermatologist. 'Implementation of AI must be underpinned by patient safety, with a clear understanding of the benefits and limitations.' The Association said that AI has 'the potential to transform dermatology services' but said that more real-world evidence is needed. It comes as Melanoma Focus warned about the dangers of sunburn among Britons. 'It is essential that everyone understands the risks associated with sunburn and prioritises sun protection by using factor 30+ sunscreen, wearing a hat, seeking shade and covering up in the heat of the day,' said Susanna Daniels, chief executive of Melanoma Focus. A poll by Melanoma Focus of 2,000 people aged 16 and over in the UK that almost half (49%) said they are sunburned at least once a year, with higher numbers reported in younger age groups. Ms Daniels added: 'This data is extremely concerning as we know that more than five sunburns in your lifetime doubles your risk of melanoma, so burning every year has potentially long-term dangerous consequences. 'Nearly nine in 10 melanomas are preventable, yet the UK has more deaths from melanoma per year than Australia.' The poll also found that 19% said they 'rarely' wear sun cream in the UK between May and September, 8% said they 'never' use sun cream in the UK during this period. Almost one in 10 (9%) said they never wear sun cream at all. Reasons for avoiding sun cream in the UK included people not expecting to burn; forgetting to apply sun cream and 8% said sun cream is 'too expensive'.
The Independent
30-04-2025
- Health
- The Independent
New AI tool to spot skin cancer to be used in NHS
Adults with suspected skin cancer may be initially assessed with a new AI tool after it was approved for NHS use. The National Institute for Health and Care Excellence (Nice) said that the technology, which has been conditionally approved for the next three years, has the potential to reduce waiting times. It comes as health experts issued a warning over sun cream ahead of the Bank Holiday weekend. Melanoma Focus said a large proportion of Britons are frequently letting themselves burn, putting themselves at a higher risk of deadly skin cancer. The new artificial intelligence (AI) tool, DERM (Deep Ensemble for Recognition of Malignancy), works by analysing images of moles or skin lesions to see whether they are potentially cancerous. The tool, developed by Skin Analytics, can be used by healthcare workers who use a smartphone with a high quality magnifying lens attached, also known as a dermoscopic lens, to take images of suspicious moles, or skin lesions. The images are then uploaded on to DERM's online platform, which uses AI to analyse the images. For patients whose moles or lesions are identified as potentially cancerous, a specialist skin doctor, known as dermatologist, will review the case and come up with a plan for the patient. People whose moles or lesions are not suspicious are either offered reassurance and advice or can be put on a 'non-urgent pathway'. Nice said that early evidence suggests the automated use of the tool could 'approximately halve the number of referrals to dermatologists within the urgent skin cancer pathway'. It has been 'conditionally approved' for the next three years, while further evidence is collected, Nice said. 'DERM has shown promising results in its ability to accurately distinguish between cancerous and non-cancerous skin lesions, with evidence suggesting it could halve the number of referrals to dermatologists within the urgent skin cancer pathway while maintaining patient safety,' said Dr Anastasia Chalkidou, healthtech programme director at Nice. 'Our evaluation shows this technology maintains diagnostic accuracy while reducing the burden on specialist dermatology services. By implementing this system within existing pathways, we can ensure patients get the right care more quickly.' Ashley Dalton, minister for public health and prevention, said: 'By embracing the power of AI, this exciting technology could help us slash waiting times — meaning that people with suspected skin cancer get the help they need, or peace of mind, faster.' Neil Daly, chief executive of Skin Analytics said: ''We're incredibly proud of the work we've been doing with the NHS over the last five years to achieve this recommendation from Nice. Having seen more than 165,000 patients and found more than more than 15,500 cancers since launching, we are ready to make our Class III autonomous skin cancer AI available to more UK patients.' The British Association of Dermatologists said in a statement: 'Until further evidence is generated, the British Association of Dermatologists recommends that all patients should have some input from a dermatologist. 'Implementation of AI must be underpinned by patient safety, with a clear understanding of the benefits and limitations.' The Association said that AI has 'the potential to transform dermatology services' but said that more real-world evidence is needed. It comes as Melanoma Focus warned about the dangers of sunburn among Britons. 'It is essential that everyone understands the risks associated with sunburn and prioritises sun protection by using factor 30+ sunscreen, wearing a hat, seeking shade and covering up in the heat of the day,' said Susanna Daniels, chief executive of Melanoma Focus. A poll by Melanoma Focus of 2,000 people aged 16 and over in the UK that almost half (49%) said they are sunburned at least once a year, with higher numbers reported in younger age groups. Ms Daniels added: 'This data is extremely concerning as we know that more than five sunburns in your lifetime doubles your risk of melanoma, so burning every year has potentially long-term dangerous consequences. 'Nearly nine in 10 melanomas are preventable, yet the UK has more deaths from melanoma per year than Australia.' The poll also found that 19% said they 'rarely' wear sun cream in the UK between May and September, 8% said they 'never' use sun cream in the UK during this period. Almost one in 10 (9%) said they never wear sun cream at all. Reasons for avoiding sun cream in the UK included people not expecting to burn; forgetting to apply sun cream and 8% said sun cream is 'too expensive'.
Western Telegraph
30-04-2025
- Health
- Western Telegraph
New AI tool to spot skin cancer to be used in NHS
The National Institute for Health and Care Excellence (Nice) said that the technology, which has been conditionally approved for the next three years, has the potential to reduce waiting times. It comes as health experts issued a warning over sun cream ahead of the Bank Holiday weekend. Melanoma Focus said a large proportion of Britons are frequently letting themselves burn, putting themselves at a higher risk of deadly skin cancer. AI is being deployed to speed up the diagnosis of skin cancer and free up capacity within dermatology. DERM assesses and classifies scans of moles or skin lesions that have been taken by a healthcare professional, after patient is referred by a GP for suspected skin cancer. — Bolton NHS Foundation Trust (@boltonnhsft) April 2, 2025 The new artificial intelligence (AI) tool, DERM (Deep Ensemble for Recognition of Malignancy), works by analysing images of moles or skin lesions to see whether they are potentially cancerous. The tool, developed by Skin Analytics, can be used by healthcare workers who use a smartphone with a high quality magnifying lens attached, also known as a dermoscopic lens, to take images of suspicious moles, or skin lesions. The images are then uploaded on to DERM's online platform, which uses AI to analyse the images. For patients whose moles or lesions are identified as potentially cancerous, a specialist skin doctor, known as dermatologist, will review the case and come up with a plan for the patient. People whose moles or lesions are not suspicious are either offered reassurance and advice or can be put on a 'non-urgent pathway'. Nice said that early evidence suggests the automated use of the tool could 'approximately halve the number of referrals to dermatologists within the urgent skin cancer pathway'. DERM has shown promising results in its ability to accurately distinguish between cancerous and non-cancerous skin lesions, with evidence suggesting it could halve the number of referrals to dermatologists within the urgent skin cancer pathway while maintaining patient safety Nice It has been 'conditionally approved' for the next three years, while further evidence is collected, Nice said. 'DERM has shown promising results in its ability to accurately distinguish between cancerous and non-cancerous skin lesions, with evidence suggesting it could halve the number of referrals to dermatologists within the urgent skin cancer pathway while maintaining patient safety,' said Dr Anastasia Chalkidou, healthtech programme director at Nice. 'Our evaluation shows this technology maintains diagnostic accuracy while reducing the burden on specialist dermatology services. By implementing this system within existing pathways, we can ensure patients get the right care more quickly.' Ashley Dalton, minister for public health and prevention, said: 'By embracing the power of AI, this exciting technology could help us slash waiting times — meaning that people with suspected skin cancer get the help they need, or peace of mind, faster.' Neil Daly, chief executive of Skin Analytics said: ''We're incredibly proud of the work we've been doing with the NHS over the last five years to achieve this recommendation from Nice. Having seen more than 165,000 patients and found more than more than 15,500 cancers since launching, we are ready to make our Class III autonomous skin cancer AI available to more UK patients.' The British Association of Dermatologists said in a statement: 'Until further evidence is generated, the British Association of Dermatologists recommends that all patients should have some input from a dermatologist. 'Implementation of AI must be underpinned by patient safety, with a clear understanding of the benefits and limitations.' The Association said that AI has 'the potential to transform dermatology services' but said that more real-world evidence is needed. It comes as Melanoma Focus warned about the dangers of sunburn among Britons. 'It is essential that everyone understands the risks associated with sunburn and prioritises sun protection by using factor 30+ sunscreen, wearing a hat, seeking shade and covering up in the heat of the day,' said Susanna Daniels, chief executive of Melanoma Focus. A poll by Melanoma Focus of 2,000 people aged 16 and over in the UK that almost half (49%) said they are sunburned at least once a year, with higher numbers reported in younger age groups. Ms Daniels added: 'This data is extremely concerning as we know that more than five sunburns in your lifetime doubles your risk of melanoma, so burning every year has potentially long-term dangerous consequences. 'Nearly nine in 10 melanomas are preventable, yet the UK has more deaths from melanoma per year than Australia.' The poll also found that 19% said they 'rarely' wear sun cream in the UK between May and September, 8% said they 'never' use sun cream in the UK during this period. Almost one in 10 (9%) said they never wear sun cream at all. Reasons for avoiding sun cream in the UK included people not expecting to burn; forgetting to apply sun cream and 8% said sun cream is 'too expensive'.
